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AIMS
The objective of this review was to collect available data on the following: (i) adverse effects observed in humans from the intake of
plant food supplements or botanical preparations; (ii) the misidentification of poisonous plants; and (iii) interactions between plant
food supplements/botanicals and conventional drugs or nutrients.
METHODS
PubMed/MEDLINE and Embase were searched from database inception to June 2014, using the terms ‘adverse effect/s’, ‘poisoning/s’,
‘plant food supplement/s’, ‘misidentification/s’ and ‘interaction/s’ in combination with the relevant plant name. All papers were
critically evaluated according to the World Health Organization Guidelines for causality assessment.
RESULTS
Data were obtained for 66 plants that are common ingredients of plant food supplements; of the 492 papers selected, 402 (81.7%)
dealt with adverse effects directly associated with the botanical and 89 (18.1%) concerned interactions with conventional drugs. Only
one case was associated with misidentification. Adverse effects were reported for 39 of the 66 botanical substances searched. Of the
total references, 86.6% were associated with 14 plants, including Glycine max/soybean (19.3%), Glycyrrhiza glabra/liquorice (12.2%),
Camellia sinensis/green tea ( 8.7%) and Ginkgo biloba/gingko (8.5%).
CONCLUSIONS
Considering the length of time examined and the number of plants included in the review, it is remarkable that: (i) the adverse effects
due to botanical ingredients were relatively infrequent, if assessed for causality; and (ii) the number of severe clinical reactions was
very limited, but some fatal cases have been described. Data presented in this review were assessed for quality in order to make the
results maximally useful for clinicians in identifying or excluding deleterious effects of botanicals.
Introduction
The use of food supplements is growing in both Europe
and the USA [1]. Food supplements can contain vitamins,
minerals, botanicals, amino acids, enzymes and many
other ingredients and are marketed in a variety of forms,
i.e. tablets, capsules and powders, as well as drops, bever-
ages and energy bars.
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Food supplements are products intended to comple-
ment the normal diet; as they are foods and not drugs,
they must not be claimed to be diagnostic, preventative
or therapeutic. The wide diffusion of food supplements
containing botanicals (plant food supplements, PFS) has
far exceeded the availability of scientific information on
their benefits, adverse effects and drug interactions. The
information on benefits may be covered partly by the ‘tra-
dition of use’, but it is more difficult to evaluate possible
adverse clinical effects due to plant properties, plant misi-
dentification or interaction with pharmaceutical drugs or
nutrients.
The first difficulty in this assessment is related to the
discrimination of plant food supplements from traditional
herbal products, because the same ingredient/product
could be sold in different countries in one or the other
category, and the relevant international legislation is not
harmonized. Even in the European Union (EU) there are
some differences in regulatory approaches [2].
Several papers have considered the adverse effects
associated with botanicals, and in some cases reviewed
data in a specific clinical area. A 5 year toxicological study
published by Shaw et al. [3] showed that among 1297
symptomatic enquiries associated with botanicals (both
food supplements and traditional remedies) there was a
possible or confirmed association in 785 cases. Some cases
of hepatotoxicity were reported following the use of
Chinese herbal medicine for skin disorders, as well as aller-
gic reactions to royal jelly and propolis and heavy metal
poisoning caused by remedies from the Indian subconti-
nent. The conclusion by Shaw et al. [3] was that although
the overall risk to public health appeared to be low, certain
groups of traditional remedies/food supplements could be
associated with a number of potentially serious adverse
effects.
Valli and Giardina [4] reviewed the adverse cardiovas-
cular events due to herbal preparations, while Pitter et al.
[5] considered food supplements aimed at bodyweight
reduction and reported adverse events including hepatic
injury and death after the use of some herbal food supple-
ments. For herbal Ephedra and ephedrine-containing food
supplements (now banned in most countries, including
the EU and the USA), an increased risk of psychiatric, auto-
nomic or gastrointestinal adverse events and heart palpi-
tations have been reported.
A one-year prospective surveillance study performed
by the Poison Center Surveillance Project evaluating
dietary supplement-related calls to the centre in 2006
showed that: (i) most supplement-related adverse events
were minor; (ii) of 275 calls, two-thirds were rated as
probably or possibly related to supplement use; (iii)
sympathomimetic toxicity was most common, with
caffeine-containing products accounting for 47% and
products containing Yohimbe spp. accounting for 18% of
supplement-related symptomatic cases; and (iv) drug–
herb interaction was suspected in some cases [6].
The European Project PlantLIBRA (Plant Food Supple-
ments: Levels of Intake, Benefit and Risk Assessment,
Project no. 245199; http://www.plantlibra.eu) aims to
foster the safe use of food supplements containing plants
or botanical preparations by increasing science-based
decision-making by regulators, researchers and food chain
operators. The aim of this systematic review is to summa-
rize and critically assess for causality the published data on
the following: (i) adverse effects related to PFS/botanical
ingredients; (ii) the misidentification of poisonous plants;
and (iii) the interactions of PFS/botanicals with pharma-
ceutical drugs or nutrients.
Materials and methods
Botanical ingredients
The plants included in this review were derived from a
consensus among partners reached after numerous meet-
ings in the framework of the PlantLIBRA EU project and
mainly represent those most commonly used in PFS. The
66 plants included in the search are listed in Table 1.
Literature search
Two of the most important scientific databases of refer-
ences and abstracts on life sciences and biomedical topics,
PubMed/MEDLINE and Embase, were systematically
searched to create the present work. The following search
strategy and selection criteria were used: data were
collected from database inception to June 2014, with
the terms ‘adverse effect/s’, ‘poisoning/s’, ‘plant food
supplement/s’, ‘misidentification/s’ and ‘interaction/s’ in
combination with the relevant plant name.
Causality assessment
The assessment of reports on adverse reactions to PFS
and/or their botanical ingredients was performed accord-
ing to the World Health Organization (WHO) Causality
Assessment Criteria as described in Table 2 [7].
Online supplementary data
The number of papers collected during the project is very
high, so that we cite only 149 papers but we offer the
whole list of papers classified according to the WHO Cau-
sality Assessment Criteria as Online Supplementary Data.
Results and Discussion
The summary of data collected from the literature and
assessed according to the WHO criteria of causality is
reported in Table 3. Reports of adverse effects were found
for 39 of 66 botanical ingredients searched, representing
59% of all the plants included in the database search. Of
the 492 papers collected, 402 (81.7%) described cases due
to adverse effects directly associated with the botanical
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and 89 (18.1%) to interactions with conventional drugs.
Only one case was associated with a misidentification of
the ingredient Passiflora incarnata [8].
Most events (426, or 86.6%) were associated with 14
botanical ingredients; the number of papers for each of
them ranged between 13 and 95.
Adverse effects due to the botanical as such or
as an ingredient of PFS
The distribution of adverse effects was different in rela-
tionship to the plant considered; Table 4 lists the number
of papers regarding specific adverse effects associated
with the botanicals searched and the relative causality
according to the WHO classification. As the use of a
rechallenge is rare or even ethically unacceptable, the
classes ‘certain’ and ‘probable/likely’ are considered
together as ‘certain/probable association’.
For the 14 most documented plants, the total number
of papers was 343, but during the evaluation the causality
was considered uncertain/unclassifiable in 61 of them;
41.4% of all the papers were associated with only two
botanicals, namely Glycine max (91) and Glycyrrhiza glabra
(51).
Adverse effects due to interaction with
nutrients or conventional drugs
Table 5 illustrates the papers regarding the interaction of
PFS/botanicals with food, beverages or conventional
drugs; assessment of causality is also reported. Of the 83
papers, 38.6% were associated with Citrus aurantium (18)
and Ginkgo biloba (14).
Form responsible for adverse effects
Table 6 lists the part of plant used and the commercial
form (botanical as such, PFS or food) associated with the
adverse effects described. In some cases, the description of
the product was limited and was carefully considered in
causality assessment.
Case reports and side-effects associated with
PFS and botanical ingredients: a review of the
top 14
As reported above, even though 39 plants (among those
searched) were associated with adverse effects, only those
reported as causal in at least 10 papers (total number in
Table 3) were considered in this review. As a consequence,
details are reported for only 14 plants, listed according to
the alphabetical order of the Latin name.
Camellia sinensis (L.) Kuntze (green tea) Numerous
papers (34) have been collected on adverse effects related
to C. sinensis (L.) Kuntze; 29 of them were considered
sufficiently documented for causality assessment. Side-
effects were associated with derivatives from green tea
leaves and involved mainly acute hepatotoxicity. Patients
showed clinical symptoms with different severity,
Table 1
Plants included in the review*
Abies alba Mill. Cynara scolymus L. Ocimum basilicum L.
Aesculus hippocastanum L. Echinacea pallida (Nutt.) Nutt. Olea europaea L.
Aloe ferox Mill. Echinacea purpurea (L.) Moench Panax ginseng C.A. Meyer
Artemisia abrotanum L. Epimedium brevicornum Maxim/sagittatum Passiflora incarnata L.
Artemisia dracunculus L. Eschscholzia californica Cham. Pelargonium sidoides DC
Borago officinalis L. Foeniculum vulgare Mill. Peumus boldus Molina
Boswellia serrata Roxb. ex Colebr. Ginkgo biloba L. Pimpinella anisum L.
Calendula officinalis L. Glycine max (L.) Merr. Plantago lanceolata L.
Camellia sinensis (L.) Kuntze Glycyrrhiza glabra L. Plantago ovata Forssk
Carica papaya L. Grindelia robusta Nutt. Pseudowintera colorata (Raoul) Dandy
Carum carvi L. Harpagophytum procumbens (Burch) DC Rhamnus purshiana DC
Cassia angustifolia M. Vahl/Cassia senna L. Helichrysum italicum (Roth) G. Don Salvia hispanica L./columbariae Benth.
Cassia obtusifolia L./Cassia tora L. Heliotropium spp. Serenoa repens (W. Bartram) Small.
Chrysanthemum balsamita (L.) Baill Hibiscus sabdariffa L. Serenoa serrulata (Michx.) Hook f.
Cichorium intybus L. Hippophae rhamnoides L. Silybum marianum (L.) Gaertn.
Cimicifuga racemosa (L.) Nutt. Humulus lupulus L. Taraxacum officinale (L.) Weber
Cinnamomum verum J. Presl (Cinnamomum zeylanicum) Hypericum perforatum L. Thymus serpyllum L.
Citrus aurantium L. Lavandula angustifolia Mill. Trifolium pratense L.
Citrus limon (L.) Burm. Lycium barbatum L. Vaccinium myrtillus L.
Citrus sinensis (L.) Osbeck Matricaria recutita L. Valeriana officinalis L.
Crataegus monogyna Jacq. Melissa officinalis L. Vitex agnus castus L.
Cuminum cyminum L. Myrtus communis L. Vitis vinifera L.
*The latin name is from the ‘The Plant List’ website (http://www.theplantlist.org).
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ranging from a mild increase of serum aminotransferase
levels to fulminant hepatitis requiring liver transplanta-
tion [9–16].
The types of preparation responsible for the adverse
effects, with different degrees of relationship, were plant
food supplements based on green tea extracts, among
which were hydroalcoholic extract [10,12–16], and
aqueous extract of green tea, consumed as tea or in cap-
sules [9, 11, 17].
Supplements were used principally for bodyweight
control and, in one case, for reducing hair loss. For tea
infusion, the daily intake was from two or three cups up to
some litres. Generally, the time of onset of the reactions
ranged from 5 days to 2 years of daily consumption. Most
cases were classified as ‘certain/probable’ or ‘possible’
when other factors could contribute to the adverse effect,
such as age, concomitant pathological conditions or
several ingredients present in the preparation. Moreover,
given that the substance involved in the adverse effect
was not always identified, an adulteration or contamina-
tion could not be excluded. For example, in two papers,
the hepatotoxicity due to two Chinese herbal supple-
ments containing tea was attributed to the presence of
N-nitroso-fenfluramine [18, 19].
Adverse effects of C. sinensis seem to be modulated by
various factors and, in particular, by the chemical compo-
sition and the type of herbal preparation. In fact, all prepa-
rations differ in their chemical composition, as follows: (i)
powdered leaves contain all the tea active components; (ii)
infusions and aqueous extracts contain mostly hydrophilic
compounds; and (iii) hydroalcoholic extracts contain both
hydrophilic and lipophilic components. The components
most frequently indicated as responsible for hepatotoxic-
ity are catechins and their gallic esters. In particular, the
role of EGCG (epigallocatechin-3-gallate) seems predomi-
nant, as shown also in experimental in vitro and in vivo
assays [20]; this conclusion could also be supported by its
high concentration in green tea extracts [21]. The associa-
tion seems further confirmed by the lack of known adverse
effects of fermented tea (black tea), in which the content of
EGCG is significantly reduced.
Interaction between green tea and conventional drugs
was recognized in nine papers; three of them with certain/
probable and six with possible causality. Most interactions
were with statins, where an increase in plasma concentra-
tion and a worsening of the related side-effects, such as
rhabdomyolysis, were observed [21, 22]. Green tea was also
responsible for interfering with a certain number of drugs,
such as warfarin, with inhibition of activity due to the
presence of vitamin K in tea [23], or acetaminophen,
with exacerbation of the hepatotoxicity [24], and other
natural compounds such as lutein [21], usnic acid and
guggulsterones [25] or Cassia angustifolia extract [26].
In the papers reporting interaction, aqueous and
hydroalcoholic extracts were the most usual forms
involved.
Cimicifuga racemosa (L.) Nutt (black cohosh) Papers
related to C. racemosa described mainly specific adverse
effects (19 of 23), and among them 14 were classified as
‘certain/probable’ and five ‘possible’.
The cases described included: (i) hepatotoxicity
[27, 28], with cases of autoimmune hepatitis [29]; (ii)
myopathy, with severe asthenia and rhabdomyolysis [30];
(iii) reversible complete heart block with bradycardia
[31]; and (iv) cutaneous vasculitis [32] and cutaneous
pseudolymphoma [33].
Adverse reactions were due to the chronic ingestion of
C. racemosa extracts, as such or as an ingredient of PFS
(Table 6). In the case of hepatotoxicity, the event was
Table 2
Causality categories according to the World Health Organization [7]
Causality classification Details
Certain A clinical event, including laboratory test
abnormality, occurring in a plausible time
relationship to drug administration, and
which cannot be explained by concurrent
disease or other drugs or chemicals. The
response to withdrawal of the drugs
(dechallenge) should be clinically plausible.
The event must be definitive
pharmacologically or phenomenologically,
using a satisfactory rechallenge procedure if
necessary
Probable/likely A clinical event, including laboratory test
abnormality, with a reasonable time
sequence to administration of the drug,
unlikely to be attributed to concurrent
disease or other drugs or chemicals, and
which follows a clinically reasonable
response on withdrawal (dechallenge).
Rechallenge information is not required to
fulfil this definition
Possible A clinical event, including laboratory test
abnormality, with a reasonable time
sequence to administrations of the drug,
but which could also be explained by
concurrent disease or other drugs or
chemicals. Information on drug withdrawal
may be lacking or unclear
Unlikely A clinical event, including laboratory test
abnormality, with a temporal relationship to
drug administration which makes a causal
relationship improbable, and in which other
drugs, chemicals or underlying disease
provide plausible explanations
Conditional/unclassified A clinical event, including laboratory test
abnormality, reported as an adverse
reaction, about which more data are
essential for a proper assessment, or the
additional data are under examination
Unassessable/unclassifiable A report suggesting an adverse reaction which
cannot be judged because information is
insufficient or contradictory, and which
cannot be supplemented or verified
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quickly reversible after discontinuation, except in two
cases where liver transplant became necessary [27, 34],
and in the case described by Lynch et al. [27] where the
event was fatal.
The possible interaction with conventional drugs is
mainly based on in vitro tests, where the inhibition of
cytochrome P450 (CYP) 3A4 activity was observed
[35].
Cinnamomum verum J. Presl (Cinnamomum zeylanicum
cinnamon) Adverse effects collected in the scientific lit-
erature for C. verum were mainly classified as events with
certain/probable causality (17 of 23, or 73.9%). Adverse
effects were mainly localized in the oral cavity and were
due to the use of cinnamon-flavoured beverages, candies
and chewing-gum. The most important adverse effects
were as follows: (i) stomatitis with swelling and burning of
lips, tongue and cheeks, with a case of ulceration [36, 37];
(ii) hyperkeratotic plaques covering most of the dorsal and
lateral tongue and involving the buccal mucosa [38]; (iii)
allergic leukoplakia of oral mucosa [39] and contact allergy
[40]; and (iv) squamous cell carcinoma of the tongue [41].
Table 3
Number of scientific papers describing adverse effects of botanicals/plant food supplements, including misidentification and interaction with nutrient or
conventional drugs
Plant by scientific name (common name)
Number of references
due to adverse
effects as such
Number of
references due to
misidentification
Number of
references due
to interactions
Total
references
Glycine max (L.) Merr (soybean) 91 0 4 95
Glycyrrhiza glabra L. (licorice) 51 0 9 60
Camellia sinensis (L.) Kuntze (tea) 34 0 9 43
Ginkgo biloba L. (ginkgo/maidenhair tree) 28 0 14 42
Citrus aurantium L. (bitter orange) 7 0 18 25
Cinnamomum verum J. Prestl (C. zeylanicum) (cinnamon) 23 0 0 23
Cimicifuga racemosa (L.) Nutt (black cohosh) 19 0 4 23
Echinacea purpurea (L.) Moench (Eastern purple coneflower) 18 0 2 20
Vitex agnus castus L. (vitex/chaste tree) 18 0 1 19
Hypericum perforatum L. (St John’s wort) 10 0 9 19
Panax ginseng C.A. Meyer (ginseng) 11 0 5 16
Valeriana officinalis L. (valerian) 6 0 8 14
Vitis vinifera L. (grape) 14 0 0 14
Harpagophytum procumbens (Burch.) DC. (Devil’s claw) 13 0 0 13
Boswellia serrata Roxb. ex Colebr. (Indian frankincense) 9 0 0 9
Serenoa repens (W. Bartram) Small. (saw palmetto) 6 0 0 6
Citrus sinensis (L.) Osbeck (sweet orange) 5 0 0 5
Taraxacum officinale (L.) Weber (dandelion) 5 0 0 5
Aesculus hippocastanum L. (horse chestnut) 2 0 2 4
Cassia angustifolia M. Vahl/Cassia senna L. (senna) 4 0 0 4
Aloe ferox Mill. (bitter aloe) 3 0 0 3
Melissa officinalis L. (lemon balm) 3 0 0 3
Passiflora incarnata L. (Passion flower) 1 1 1 3
Peumus boldus Molina (boldo) 1 0 2 3
Cassia obtusifolia L./Cassia tora L. (sickle senna/Java bean) 2 0 0 2
Foeniculum vulgare Mill. (fennel) 2 0 0 2
Matricaria recutita L. (chamomile) 1 0 1 2
Ocimum basilicum L. (sweet basil) 2 0 0 2
Olea europaea L. (olive) 2 0 0 2
Silybum marianum (L.) Gaertn (milk thistle) 2 0 0 2
Borago officinalis L. (borage) 1 0 0 1
Crataegus monogyna Jacq. (hawthom) 1 0 0 1
Cynara scolymus L. (globe artichoke) 1 0 0 1
Echinacea pallida (Nutt.) Nutt. (pale purple coneflower) 1 0 0 1
Pelargonium sidoides DC. (Umckaloab) 1 0 0 1
Pimpinella anisum L. (anise) 1 0 0 1
Plantago lanceolata L. (ribwort plantain) 1 0 0 1
Rhamnus purshiana DC. (cascara sagrada) 1 0 0 1
Trifolium pratense L. (red clover) 1 0 0 1
Total 402 1 89 492
C. Di Lorenzo et al.
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Some contact dermatitis was experienced after con-
sumption of cinnamon-flavoured food or solutions [42] or
PFS containing C. verum oil [43]. One case of intoxication
was observed in a child [44]. No case of interaction with
nutrients or conventional drug was found.
Citrus aurantium L. (bitter orange) Specific adverse
effects (seven) and interaction with conventional drugs
(18) have been reported. The most usual adverse reactions
were in the cardiovascular system, including hypertension,
tachycardia and ventricular extrasystoles [45]. Ischaemic
colitis [46], allergic bronchospasm [47] and hepatitis with
massive necrosis [45] were also reported.
Attempted weight loss was the most common reason
for using PFS containing C. aurantium. In one case, the
subject used a decoction of leaves to treat a common cold
[48]. An extract of ripe or unripe fruit (usually unspecified)
was the most usual form taken by consumers. The pres-
ence of stimulant amines, such as synephrine and
octopamine, in C. aurantium explains the numerous
adverse cardiovascular effects. The chemical structure of
synephrine resembles that of the neurotransmitter
adrenaline and of the alkaloid ephedrine, so that it acts as
a sympathomimetic substance [49].
When C. aurantium was used in combination with caf-
feine, ephedrine, yohimbine and phenylethylamine, but
Table 4
Number of papers describing specific adverse effects to the botanicals considered and their ranking by causality*
Plant by scientific name (common name)
Total number of
papers describing
side-effects
Papers reporting
certain/probable
association
Papers reporting
possible association
Papers showing
unlikely/unassessable
association
Glycine max (L.) Merr. (soybean) 91 58 11 22
Glycyrrhiza glabra L. (licorice) 51 38 11 2
Camellia sinensis (L.) Kuntze (tea) 34 15 14 5
Ginkgo biloba L. (ginkgo/maidenhair tree) 28 19 4 5
Cinnamomum verum J. Presl (zeylanicum) (cinnamon) 23 17 2 4
Vitex agnus castus L. (vitex/chaste tree) 18 13 1 4
Echinacea purpurea (L.) Moench (Eastern purple coneflower) 18 8 0 10
Cimicifuga racemosa (L.) Nutt. (black cohosh) 19 14 5 0
Vitis vinifera L. (grape) 14 14 0 0
Harpagophytum procumbens (Burch.) DC. (Devil’s claw) 13 13 0 0
Hypericum perforatum L. (St John’s wort) 10 4 6 0
Panax ginseng C.A. Meyer (ginseng) 11 1 6 4
Citrus aurantium L. (bitter orange) 7 5 0 2
Valeriana officinalis L. (valerian) 6 1 2 3
Total 343 220 62 61
*Owing to the high number of citations, the whole list of papers is organized for plant and causality in the Online Supplementary Data.
Table 5
Number of papers reporting interactions between the botanicals considered and nutrients, food or conventional drugs with ranking by causality*
Plant by scientific name (common name)
Total number
of papers describing
interactions
Papers reporting
certain/probable
association
Papers reporting
possible association
Papers showing
unlikely/unassessable
association
Citrus aurantium L. (bitter orange) 18 6 11 1
Ginkgo biloba L. (ginkgo/maidenhair tree) 14 7 3 4
Glycyrrhiza glabra L. (licorice) 9 6 2 1
Camellia sinensis (L.) Kuntze (tea) 9 3 6 0
Hypericum perforatum L. (St John’s wort) 9 6 3 0
Valeriana officinalis L. (valerian) 8 0 4 4
Glycine max (L.) Merr. (soybean) 4 1 2 1
Cimicifuga racemosa (L.) Nutt. (black cohosh) 4 0 4 0
Panax ginseng C.A. Meyer (ginseng) 5 1 4 0
Echinacea purpurea (L.) Moench (Eastern purple coneflower) 2 1 1 0
Vitex agnus castus L. (vitex/chaste tree) 1 0 0 1
Total 83 31 40 12
*Owing to the high number of citations, the whole list of papers is organized for plant and causality in the Online Supplementary Data.
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also thyroxine, enhancement of the adverse effects was
reported, with stimulant cardiovascular effects, such as
tachycardia and hypertension [50], ventricular fibrillation
[51], angina [52], acute myocardial infarction [53],
ischaemic stroke [54] and exercise-induced syncope [55].
Less frequently described were rhabdomyolysis [45],
ischaemic colitis [56] and psychosis [57].
Cases of adverse effects of C. aurantium were mainly
classified as ‘possible’ due to the frequent presence of
accompanying conditions, such as obesity, hypothyroid-
ism, asthma, diabetes, hypertension, hyperlipidaemia,
alcoholism, drug abuse, depression, anxiety, nicotine use
and dehydration.
Echinacea purpurea (L.) Moench (Eastern purple cone-
flower) The review selected a total of 20 papers reporting
adverse effects due to E. purpurea. They were mainly
associated with ethanolic extracts of the root and herb,
but adverse reactions to aqueous extracts were also
reported. Causality was often (10 of 20) defined as
‘unclassifiable’ because of the lack of clear information on
the botanical preparation, description of the adverse
event, patient’s anamnesis or insufficient evidence of
exposure. The lack of data could be explained partly by
the fact that many adverse effects were found in papers
from regulatory bodies, where details on the specific
E. purpurea preparation were not included. Among
others: WHO, Adverse Drug Reactions Advisory
Commitee (ADRAC), Bundesinstitut fur Arzneimittel und
Medizinprodukte (BfArM), Food and Drug Administration
(FDA).
Adverse reactions were associated with both allergy and
hepatic or gastrointestinal effects. Allergic reactions were
mainly due to IgE-mediated hypersensitivity [58] and could
be due to the known immunostimulating properties of
E. purpurea. Echinacea derivatives stimulate macrophage
and enhance cytokine production, which could be responsi-
ble for adverse consequences in humans [59]. Hepatotoxicity
Table 6
Form used by consumers experiencing adverse effects
Plant by scientific name (common name)
Botanical part used
(when specified)
Food and beverages
(functional, flavoured etc.) Plant food supplement (type) Other
Camellia sinensis (L.) Kuntze (tea) Leaves Tea (high quantity) Capsules containing micronized
leaf powder or different extracts
Aqueous, ethanolic or
hydroalcoholic extracts
Cimicifuga racemosa (L.)
Nutt. (black cohosh)
Rizhoma – Capsules containing six plants,
including C. racemosa
Standardized unspecified
extract
Cinnamomum verum J. Presl
(zeylanicum) (cinnamon)
Bark Flavoured candies and foods;
sweet vermouth and coffee
Plant foot supplement
(containing oil)
Oil, chewing-gum,
toothpaste, mounthrinse
Citrus aurantium L. (bitter orange) Ripe and unripe fruit,
fruit rind
– – Unspecified extracts,
decoction
Echinacea purpurea (L.) Moench
(Eastern purple coneflower)
Root or coneflower Juice Juice combined with
other ingredients
Hydroalcoholic, aqueous or
unspecified extracts
Ginkgo biloba L.
(ginkgo/maidenhair tree)
Leaves, seeds Roasted ginkgo seeds,
microwave cooked seeds
Plant foot supplement
containing extracts
Extracts, ginkgolide mixtures
Glycine max (L.) Merr. (soybean) Seeds Soybean protein-based formula,
soybean ‘milk’, Miso
(fermented soybean),
Tofu, Baloney (sausage)
Supplements containing
soybean isoflavones
Lecithins, soybean protein
concentrates, soybean
granules, soybean flour
Glycyrrhiza glabra L.
(licorice)
Root Licorice rope and candies,
juices, drinks,
Pontefract cake
Plant foot supplement tablets,
‘herbal tonic’
Chewing-gum, decoction,
concentrated juice
Harpagophytum procumbens (Burch.) DC.
(Devil’s claw)
Tuber, root tuber,
secondary tuber,
whole plant
– Capsules containing extract
from whole plant
Aqueous extract, ethanol
extract, powder from root
or secondary tubers
Hypericum perforatum L.
(St John’s wort)
Flowering herb – Tablets, unspecified preparations,
including an extract enriched
in hyperforin
Unspecified extracts
Panax ginseng C.A. Meyer
(ginseng)
Root Candies and teas Ginseng syrup Dry root, extracts (from
standardized to
unspecified), chewing-gum
Valeriana officinalis L.
(valerian)
Root – Infusions Raw root material
Vitex agnus castus L.
(vitex/chaste tree)
Fruit – – Ethanolic/aqueous extracts
Vitis vinifera L. (grape) Fruit and leaves Fresh and dry fruit, juices – Aqueous extract,
hydroalcoholic extract;
unspecified skin extract
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was described as an acute event, with features of cholestatic
autoimmune hepatitis [60], and as a case of fatal liver necro-
sis [61]. Other clinical manifestations probably associated
with E. purpurea were a case of erythema nodosum [62],
diarrhoea, vomiting, headache and drowsiness [63].
The possible interaction of E. purpurea with pharma-
ceutical drugs was considered by some authors. Gorski
et al. [64] considered that the observed induction of
CYP3A4 activity explained the interaction of unspecified
root extracts with various medications, such as tolbuta-
mide, midazolam (oral or intravenous administration)
and dextromethorphan. Other interactions with albuterol,
allopurinol, beclomethasone, dihydrocodeine and
roxithromycin were evaluated as unclassifiable because of
the lack of clinical details [58].
In contrast, Gurley et al. [65] found there to be no sig-
nificant effect of E. purpurea on the activity of cytochromes
CYP3A4, CYP1A2, CYP2E1 or CYP2D6. The incongruence
with the results of Gorski et al. [64] is probably due to the
different type of extracts used; Gorski et al. [64] used the
root extract (containing >1% phenols as cichoric acid,
chlorogenic acid and echinacoside), while Gurley et al. [65]
used the whole plant extract, containing principally
cichoric acid.
Ginkgo biloba L. (Ginkgo/maidenhair tree) The review of
adverse effects associated with Ginkgo biloba produced 42
papers, 28 related to adverse effects of the plant derivative
as such and 14 reporting an interaction with conventional
drugs. Most of them (33) were classified as events with
certain/probable and possible causality. Leaves and seeds
are the parts most usually consumed, both as such
(roasted or cooked seeds) and as extracts. The type of
extract is normally undefined apart from the study by
Yagmur et al. [66], in which the product is specifically indi-
cated (EGb761). Adverse reactions are usually associated
with haemorrhagic complications [67, 68], with one case of
a subdural haematoma [69]. The activity is probably due to
the antiplatelet activity of ginkgosides, and ginkgolide B
seems to be the main terpenoid responsible for such
effects [69, 70].
In some papers, other symptoms were identified, as
follows: acute generalized exanthematous pustulosis [71];
toxic epidermal necrolysis [72]; ventricular arrhythmia [73];
and convulsions [74]. An increased risk of bleeding compli-
cations was observed when G. biloba was taken concomi-
tantly with other conventional drugs acting on
coagulation, such as acetyl salicylic acid [75, 76], ibuprofen
[77] and warfarin [78]. A subtherapeutic level of
anticonvulsants (phenytoin and valproic acid), due to an
induction of CYP2C19 by ginkgo active compounds, was
also observed in a case of fatal breakthrough seizure [79].
Glycine max (L.) Merr. (soybean) The review produced
95 papers reporting adverse effects associated with the
consumption of Glycine max; among these, only a few (4)
documented an interaction with nutrients or drugs. In par-
ticular, a decreased absorption of levothyroxine was attrib-
uted to the use of a food supplement containing
soybean proteins [80], while ingestion of soy ‘milk’ and
seaweed was associated with serious thyroid dysfunction
[81]. Moreover, foods containing soybean and its
isoflavones were responsible for bleeding when combined
with estradiol [82]. During a clinical trial of the effect of soy
isoflavones and melatonin in relieving menopausal symp-
toms, one patient experienced tachycardia, weight gain,
insomnia, drowsiness and headache [82].
The adverse effects due to G. max are mainly associated
with the well-known allergenic potential of this legume
(30/91), which is used as an ingredient in several foods and
preparations, such as soy ‘milk’, paediatric formulas and
lecithin [83, 84]. Soybean is included in the list of major
allergens requiring specific labelling, and the proteins
responsible for the allergic reactions have been widely
studied (IUIS Allergen Nomenclature Sub-Committee;
http://www.allergen.org/search.php?allergensource=
Glycine+max) and identified [84].
The second most important group of side-effects due to
soybean derivatives is associated with the isoflavone fraction
[85, 86]. Glycine max isoflavones are frequently contained in
food supplements aimed at reducing menopause-related
symptoms and diseases. Side-effects due to their
pseudohormonal activity have been observed in both
females and males; in particular, precocious thelarche [87],
uterine fibroids [88], ureteral Müllerian carcinosarcoma asso-
ciated with endometriosis [89], gynaecomastia [90],
hypogonadism and erectile dysfunction [91], testicular
cancer and reproductive disorders [85, 87].
Other case reports associated with G. max, with satis-
factory demonstration of causality, are as follows: (i)
gastrointestinal adverse effects, including enterocolitis,
vomiting, abdominal pain and diarrhoea, gastric cancer
and hepatitis [92–95]; (ii) thyroid dysfunction caused by
the consumption of soybean ‘milk’ containing high levels
of iodine [96]; (iii) bladder cancer [97]; and (iv) cases
with different symptoms, such as hypophosphataemia
in very-low-birthweight infants, fatal hypernatraemia,
migraine, hypochloraemic alkalosis and transient
methaemoglobinaemia [98–101].
Glycyrrhiza glabra L. (liquorice) The review selected 60
papers reporting adverse reactions (specific reactions and
interactions) after the consumption of liquorice. Most of
them were classified as certain/probable (44), and only
three were deemed ‘unlikely’. The root is the plant part
used; sweets, chewing gum, drinks and PFS are the most
usual forms consumed, but data on the preparation is not
always included in papers. Most adverse events had the
same symptomatic pattern, which is attributable to the
biological activity of glycyrrhetic acid. Hypokalaemia and
hypertension are the most frequent adverse events [102,
103], which can be worsened by the concomitant use of
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conventional drugs, such as bendrofluazide [104], hydro-
chlorothiazide [105] or other diuretics [106]. Interaction
with oral contraceptives, with a similar clinical pattern
(hypokalaemia and water retention), has also been
reported [107]. In some cases, the clinical evolution
was particularly severe, with rhabdomyolysis [108],
hypokalaemic paralysis [109], hypokalaemic encephalopa-
thy [110] and cardiac arrest [111].
The adverse effects are mainly due to the active com-
pound in liquorice, glycyrrhetic acid, which inhibits the
11β-hydroxysteroid dehydrogenase type 2 enzyme that is
present in the principal cells of the cortical collecting duct.
Given that cortisol and aldosterone are similar steroid hor-
mones, the enzyme is needed to inactivate cortisol before
it binds the aldosterone receptor inside principal cells.
When 11β-hydroxysteroid dehydrogenase type 2 is
inhibited, an aldosterone-like effect is promoted, which
suppresses the renin–angiotensin–aldosterone axis and
causes volume expansion, hypertension, hypokalaemia
and metabolic alkalosis [112].
Harpagophytum procumbens (Burch.) DC. (Devil’s
claw) Case reports associated with this botanical mainly
refer to the treatment of low back pain or arthrosis of the
hip and knee. All studies were classified as probable/likely
and were associated with derivatives of the tuber or the
whole plant (extracts or PFS; see Table 6). Acting as a cyclo-
oxygenase 2 inhibitor, adverse effects associated with
H. procumbens preparations, which were predictable and
dose dependent, included mainly gastrointestinal disor-
ders [113]. Throbbing frontal headache, tinnitus, anorexia
and loss of taste for food were described in one patient by
Grahame and Robinson [114].
Hypericum perforatum L. (St John’s wort) Among the
10 papers describing specific adverse effects associated
with H. perforatum, four (40%) were classified as certain/
probable and six as possible. The best-described cases
reported convulsions and confusion [115], manic attack
[116] and hypertension with [117] or without delirium
[118]. Other authors described sexual dysfunction [119],
serotonin syndrome-like symptoms with anxiety, hyper-
tension, tachycardia and nausea [120] and, finally, a 5-fold
increase of transaminases [121].
Several authors reported clinical cases of patients suf-
fering from adverse effects due to an interaction between
H. perforatum and drugs. The events were considered
certain/probable in six of the nine cases and possible in the
other three. It has been shown that there may be clinically
significant drug–drug interactions between H. perforatum
and substances metabolized through the CYP3A4
isozyme. Specifically, reductions in therapeutic efficacy at
standard doses of important CYP3A4 substrates may be
observed [122].
When H. perforatum was used in combination with
drugs, reduced bioavailability was shown for the
following: verapamil [123], glicazide, nifedipine,
omeprazole, voriconazole, anticoagulant drugs such as
phenprocoumon and warfarin, statins such as atorvastatin
and simvastatin [124], talinolol [125], digoxin [124, 126],
nevirapine [127], contraceptive drugs, cyclosporine,
tacrolimus and theophylline [124, 126] and loperamide
together with Valeriana officinalis [128]. Other authors
described an interaction with selective serotonin reuptake
inhibitors to produce serotonin syndrome [126]. In addi-
tion, long-term use of H. perforatum was considered
responsible for adrenergic desensitization and decreased
responsiveness to vasopressors, leading to cardiovascular
collapse in a patient during anaesthesia [129]. Further
interactions producing a decrease of bioavailability were
suggested by Hu et al. [126] with amitriptyline, alprazolam,
midazolam, fexofenadine, imatinib, irinotecan, metha-
done, indinavir and quazepam.
Panax ginseng C.A. Meyer (ginseng) The adverse effects
collected in the scientific literature for ginseng can be clas-
sified as specific effects in 11 cases and as an interaction
with conventional drugs in five.
Among the 11, one was classified as certain/probable
and six as possible; the remaining four papers were not
sufficiently documented. The part of the plant used is the
root, and little information is normally included about the
method of preparation. The adverse reactions described
were as follows: stimulant effects, such as nervousness and
tremor, a maniacal episode in a patient with recurrent
depressive illness [130], metrorrhagia [131] and allergic
reactions, including generalized urticarial rash and diffi-
culty in breathing [132].
Clinical events associated with co-administration of
P. ginseng with conventional drugs included interaction
with the anticoagulant drug warfarin [133], the antidepres-
sant drugs phenelzine [134] and clomipramine [135]
inducing manic symptoms, and the tyrosine kinase inhibi-
tor imatinib, responsible for liver damage via an interac-
tion with CYP3A4 [136].
Valeriana officinalis L. (valerian) Cases were classified as
specific adverse effects in six of 14 papers or interaction
with nutrient and conventional drugs in the remaining
eight. Causality of the adverse effects was rarely docu-
mented, likewise the kind of product used by the patient.
The case classified as certain/probable reported hepato-
toxicity [137], including a fulminant hepatic failure [138].
Among the cases of interaction with conventional
drugs, nutrients or food/beverages, only four cases were
considered sufficiently documented; they were cases
of the following: (i) hypotension due to an interaction
with Matricaria chamomilla and Melissa officinalis [139];
(ii) hand tremor, dizziness and muscular fatigue due
to co-administration with Passiflora incarnata and
lorazepam [140]; (iii) change of mental status due to con-
sumption together with alcohol and G. biloba [141]; and
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(iv) hepatitis due to interaction with Scutellaria lateriflor,
containing alkylating agents, glycoside and volatile oils
[34].
Vitex agnus castus L. (vitex or ‘chaste tree’) Nineteen
papers described adverse effects of V. agnus castus. Some
of them were observed during clinical studies performed
during postmarketing surveillance. This is because in
several European countries V. agnus castus is included
among botanical ingredients used in traditional medicine
(mainly Germany and Austria), requiring marketing
authorization. All these products contain ethanolic
extracts of the fruit of V. agnus castus and are used for
premenstrual syndrome. Adverse effects reported vary
widely; the most frequent and documented clinical events
are as follows: (i) intermenstrual bleeding or disorders
[142–144]; (ii) gastrointestinal disorders with diarrhoea,
persistent gastroenteritis and nausea [142, 144, 145]; (iii)
acneform facial inflammation [145]; (iv) headache [144]; (v)
weight gain [142, 144, 145]; (vi) dizziness [142, 145]; and
(vii) allergic reactions with pruritus, erythema and gastro-
intestinal symptoms [143]. Other, less frequent adverse
effects were arteriospasm and hepatitis [146].
Causality between plant intake and adverse effects was
considered certain/probable in most cases (13 of 18),
because the adverse effects were registered during well-
controlled clinical studies, and the plant was often the only
‘treatment’ used.
Vitis vinifera L. (grape) All papers collected for effects of
this botanical (14) were classified as ‘certain/probable’. Most
of them can be considered as allergic reactions, including
oral syndrome, urticaria, angioedema, hypotension and res-
piratory distress, anaphylaxis and exercise-induced anaphy-
laxis [147–149]. The most important allergens from
grapevine are endochitinase A and B, a lipid transfer protein
and a thaumatin-like protein [148]. No interaction with nutri-
ents or conventional drugs has been described.
Conclusions
At the first step in searching databases for adverse effects
of the 66 botanical ingredients considered (Table 1), some
thousands of papers were considered. With the applica-
tion of WHO assessment criteria (Table 2), the number of
papers with sufficient evidence of a causal relationship
was reduced to 492 for 39 plants (see Table 3). No paper
describing significant adverse effects was found for the
remaining 27 plants. Fourteen plants were the most fre-
quently cited, and among them, two were responsible for
32% of the adverse effects reported.
1 Glycine max (soybean) was considered in 95 papers,
where its role in allergic reactions and hormone-like
activity was demonstrated. Both effects are well known;
in fact, soybean is included in the list of major food aller-
gens, and the hormonal activity of phytoestrogens is the
reason that it is used in menopause.
2 Glycyrrhiza glabra (liquorice) was usually responsible for
hypokalaemia and hypertension due to its content of
glycyrrhetic acid. The hypertensive potential of liquorice
and its interaction with conventional drugs are also quite
well known in clinical practice.
Generally speaking, we could draw the following
conclusions.
1 Cases of adverse effects of botanicals are numerous, in
term of citations by scientific literature or phytovigilance
centres, but an assessment according to the WHO crite-
ria indicates that the number of those with adequate
evidence for a causal relationship is significantly less.
2 Given the long period of time considered and the number
of plants included in the review, the occurrence of adverse
effects of botanical ingredients is relatively low.
3 The number of severe clinical reactions is very limited,
but some fatal cases have been described.
4 It is important to recognize that an underestimation is
also possible, for the following reasons: (i) the consumer
usually considers botanicals as safe products and
does not report their use if they are admitted to hospital
or emergency service; (ii) as they use PFS at their own
discretion, consumers could avoid informing the family
doctor, fearing a reprimand; (iii) data collected by poison
centres are published only in a relatively few cases.
Despite these apparently reassuring findings, we still
consider it is important to direct the attention of clinicians to
the possibility of rare but severe adverse effects from botani-
cal preparations or ingredients of food supplements or tra-
ditional medicines. For example, the severe hepatotoxicity of
C. sinensis (green tea) was unknown before the product
Exolise, containing a hydroalcoholic extract, was marketed
and which was found to be responsible for a number of cases
of acute hepatitis in France and Belgium [13, 17]. Although
very rare (considering the large number of green tea con-
sumers in the world), the severity of these reactions needs
information and vigilance. Likewise, C. aurantium, which
contains adrenergic amines, must be considered a potential
risk both for athletes and for the general population, taking
into consideration the possible abuse as a substitute for the
products containing Ephedra, now banned.
Data presented in this review were assessed for quality,
in order to be of maximal value for clinicians and the clini-
cal management of affected patients.
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